Marcelo Bravo, Chief Executive, provides an update on the Company and recent progress with the plans to commercialise its non-steroidal anti-inflammatory drug (NSAID) molecules, known as OXPzero™.
Marcelo Bravo, Chief Executive, provides an update on the Company and recent progress with the plans to commercialise its non-steroidal anti-inflammatory drug (NSAID) molecules, known as OXPzero™.
